TRxADE HEALTH Inc.
Find Ratings ReportsTRXADE HEALTH INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. TRXADE HEALTH INC has very weak liquidity. Currently, the Quick Ratio is 0.25 which clearly shows a lack of ability to cover short-term cash needs. The liquidity decreased from the same period a year ago, despite already having weak liquidity to begin with. This would indicate deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 726.30% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 2.06 | 2.06 |
EBITDA ($mil) | -0.52 | -0.32 |
EBIT ($mil) | -0.85 | -0.34 |
Net Income ($mil) | -3.53 | -0.5 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 0.03 | 0.32 |
Total Assets ($mil) | 21.65 | 4.69 |
Total Debt ($mil) | 6.94 | 2.17 |
Equity ($mil) | 11.56 | 1.4 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | -25.12 | 67.61 |
EBITDA Margin | -25.12 | -15.75 |
Operating Margin | -41.06 | -16.59 |
Sales Turnover | 0.39 | 2.21 |
Return on Assets | -32.57 | -71.03 |
Return on Equity | -25.35 | -193.57 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 0.61 | 1.15 |
Debt/Capital | 0.38 | 0.61 |
Interest Expense | 0.25 | 0.13 |
Interest Coverage | -3.35 | -2.62 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 0.82 | 0.56 |
Div / share | 0.0 | 0.0 |
EPS | -0.07 | -0.6 |
Book value / share | 14.11 | 2.5 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 414711.0 | 15520.0 |
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 2.07 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 17.67. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the subsector average, indicating a discount. After reviewing these and other key valuation criteria, TRXADE HEALTH INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MEDS NM | Peers 76.09 | MEDS 28.77 | Peers 32.96 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. MEDS's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. MEDS is trading at a discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
MEDS NA | Peers 26.19 | MEDS NA | Peers 0.62 | |||||||||||||||||||||
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential. Ratio not available. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
MEDS 2.07 | Peers 17.67 | MEDS 17.06 | Peers 89.51 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. MEDS is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, MEDS is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
MEDS 2.83 | Peers 8.21 | MEDS -18.62 | Peers 15.59 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. MEDS is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. MEDS significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||